BRL 44154
Latest Information Update: 02 Jul 2023
Price :
$50 *
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antibacterials
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 02 Jun 1995 Discontinued-I for Bacterial infections in United Kingdom (Parenteral)
- 31 May 1995 New profile
- 31 May 1995 Phase-I clinical trials for Bacterial infections in United Kingdom (Unknown route)